Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment: The RALU Study

© 2023 by the Society of Nuclear Medicine and Molecular Imaging. Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.

Author Information

¹Department of Nuclear Medicine, University of Münster Medical Center, Münster, Germany;
²Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany;
³Department of Nuclear Medicine, German Cancer Consortium (DKTK) University Hospital Essen, Essen, Germany;
⁴Department of Nuclear Medicine, Technical University of Munich, Munich, Germany;
⁵Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tübingen, Tübingen, Germany;
⁶Department of Nuclear Medicine, University of Ulm, Ulm, Germany;
⁷International Centers for Precision Oncology Foundation, Ravensburg, Germany;
⁸Department of Nuclear Medicine, Medical Faculty, University of Augsburg, Augsburg, Germany;
⁹Bayer HealthCare Pharmaceuticals, Whippany, New Jersey;
¹⁰Bayer Consumer Care, Basel, Switzerland; and
¹¹Tulane Cancer Center, Tulane Medical School, New Orleans, Louisiana

For correspondence or reprints, contact Kambiz Rahbar (kambiz.rahbar{at}ukmuenster.de).